Using 5 Green Strategies, This Pharmaceutical Issuer Achieves Significant Performance in 2025
JAKARTA, KOMPAS.com – The pharmaceutical issuer PT Phapros Tbk (PEHA) has revealed five sustainability-based strategies that not only mitigate environmental impact but also result in significant improvements to financial performance throughout 2025.
These strategies are implemented through operational efficiency, technological innovation, and more measured waste management. As a result, the company managed to reverse its performance from a loss to a profit within one year.
Acting President Director of PT Phapros Tbk, Ida Rahmi Kurniasih, emphasised that sustainability is an integral part of the business strategy to strengthen the company’s fundamentals.
“We are proud to have once again received the Proper Hijau award as a manifestation of Phapros’s commitment to implementing sustainable and environmentally friendly practices,” said Ida, in a press statement on Monday (13/4/2026).
“Leadership is a key factor in ensuring that operations at Phapros always adhere to environmental aspects while realising sustainable company performance growth,” she continued.
These steps began with adjusting the chiller capacity using environmentally friendly refrigerant, which saved up to 1,055.23 GJ of energy. Efforts continued with transforming boiler technology to be more efficient in fuel use, as well as modifying syringe filters for repeated use.
The company also utilised reverse osmosis concentrate water for domestic needs that was previously wasted as effluent, and reformulated packaging materials to reduce non-hazardous waste by 6.73 tonnes.
Overall, throughout 2025, Phapros implemented 16 energy efficiency programmes amounting to 33,824.80 GJ and 16 emission reduction programmes amounting to 3,442.74 tonnes of CO2e. Hazardous waste reduction reached 17.62 tonnes, while non-hazardous waste management amounted to 121.31 tonnes through the 3R programme.
The impact is evident in financial performance. For January–December 2025, Phapros recorded a 109% surge in net profit compared to the same period in the previous year, which still reported a loss of Rp 290.63 billion. This achievement also far exceeded the 2023 performance, which only recorded a profit of Rp 6.01 billion.
On the sales side, the company booked Rp 940.88 billion in 2025, growing 26.34% year-on-year. Growth occurred across all segments, namely over-the-counter medicines (OTC) up 43.20%, generic branded medicines (OGB) growing 13.95%, and the ethical segment increasing 54.94%.
Cost efficiency is also reflected in the reduction of cost of goods sold to Rp 448.37 billion from Rp 474.03 billion. Operating expenses were successfully reduced by 14.64% to Rp 406.43 billion from Rp 476.12 billion in 2024.
“The spirit of recovery unites our goals to yield positive results. This achievement is the result of five consistent performance improvement strategies implemented by the company,” said Ida.
“Business fundamental improvements have driven sales growth in all segments, thus successfully restoring the company’s sustainable profitability,” she continued.
She added that business transformation, product portfolio optimisation, and distribution efficiency are key to maintaining growth momentum going forward.